Showing 1071-1080 of 20877 results for "".
- MenACYW-TT Coadministration Trial Reports Non-Inferior Immune Responseshttps://reachmd.com/news/menacyw-tt-coadministration-trial-reports-non-inferior-immune-responses/2487412/Key Takeaways Both co-primary non-inferiority endpoints were met at the prespecified 6-month and 12- to 15-month assessments. Routine pediatric vaccine responses were also non-inferior with MenACYW-TT coadministration. Reactogenicity and broad
- Maternal RSV Vaccination, Nirsevimab in Infants, and Sequential Administrationhttps://reachmd.com/news/maternal-rsv-infant-nirsevimab/2487394/Key Takeaways A prospective randomized phase 4 comparison examined maternal vaccination, infant nirsevimab, and sequential administration in enrolled mother-infant pairs. No related serious adverse events were seen in mothers or infants, and infant nir
- Thrive Trial Shows Increase in Home Health Referrals for Medicaid Patientshttps://reachmd.com/news/thrive-home-health-referrals-medicaid/2487391/Key Takeaways Trained discharge planners were more likely to refer eligible patients to home health services than planners who had not yet entered the intervention. Implementation ratings were uniformly high, with acceptability, appropriateness, and fe
- Buprenorphine After Ketamine for Suicidal Ideation in MDDhttps://reachmd.com/news/buprenorphine-ketamine-suicidal-ideation-mdd/2487395/Key Takeaways Greater improvement in SSI total score was observed with buprenorphine than with placebo after ketamine. Depression scores did not differ significantly between groups. No serious treatment-related adverse events were reported.
- Linerixibat Improved Pruritus in Phase 3 PBC Trialhttps://reachmd.com/news/linerixibat-improved-pruritus-in-phase-3-pbc-trial/2487359/Key Takeaways Linerixibat was associated with greater pruritus improvement than placebo over 24 weeks. Gastrointestinal adverse events, especially diarrhea, were reported more often with linerixibat than with placebo. The randomized phase 3 co
- Ultra-Processed Food Intake and Mortality in the PLCO Cohorthttps://reachmd.com/news/ultra-processed-food-intake-and-mortality-in-the-plco-cohort/2487360/Key Takeaways Higher ultra-processed food intake was associated with modestly higher all-cause mortality in this cohort. Higher risks were also observed for circulatory system, nervous system, and other-cause mortality, while cancer mortality was not a
- Telehealth and Online CBT for High-Impact Chronic Painhttps://reachmd.com/news/telehealth-and-online-cbt-for-high-impact-chronic-pain/2487368/Key Takeaways Both remote 8-session CBT-based programs were associated with higher 3-month clinically important pain response rates than usual care. The health coach-led program showed better primary endpoint performance than the self-completed online
- Technology-Based Dry Eye Interventions Rank Differently by Outcomehttps://reachmd.com/news/technology-based-dry-eye-interventions-rank-differently-by-outcome/2487377/Key Takeaways Different technologies led different short-term endpoints, with TearCare plus meibomian gland expression topping gland secretion and IPL alone ranking highest for symptom relief. IPL-based approaches were associated with better tear break
- SCRATCH-AD: Rapid Itch Reduction, Biomarker Improvements with Ruxolitinibhttps://reachmd.com/news/scratch-ad-rapid-itch-reduction-biomarker-improvements-with-ruxolitinib/2487381/Patients with atopic dermatitis (AD) treated with ruxolitinib 1.5% cream experienced rapid and sustained reductions in itch alongside improvements in disease-associated biomarkers, according to findings from the SCRATCH-AD study. The open-label SCRATCH-AD trial (NCT04839380) evaluated the
- Avapritinib Shows Dermatologic Benefits in Indolent Systemic Mastocytosishttps://reachmd.com/news/avapritinib-shows-dermatologic-benefits-in-indolent-systemic-mastocytosis/2487380/Treatment with avapritinib led to substantial improvements in cutaneous disease manifestations among patients with indolent systemic mastocytosis (ISM), according to results from the phase 2 PIONEER study. Investigators for